Social Capital Suvretta Holdings Corp. IV Stock: price and management transactions · United States · SEC (Form 4)

About Social Capital Suvretta Holdings Corp. IV

Social Capital Suvretta Holdings Corp. IV was a U.S.-listed special purpose acquisition company, initially priced and traded on the NASDAQ Capital Market under the ticker DNAD in June 2021. The company was organized as a Cayman Islands exempted company, with its operating headquarters presented in Palo Alto, California, placing it squarely within the U.S. public-markets and Silicon Valley SPAC ecosystem. Its original mandate was not to run an operating business, but to pursue a merger, share exchange, asset acquisition, or similar business combination with one or more target companies. At the IPO stage, the sponsor explicitly framed the acquisition focus around biotechnology, with emphasis on the immunology subsector. The SPAC was backed by Social Capital, associated with Chamath Palihapitiya, and Suvretta Capital, with Chamath Palihapitiya and Kishen Mehta presented as the principal leaders. In market terms, that sponsor combination mattered because SPAC investors were buying into a sourcing platform: access to deal flow, sponsor credibility, and the potential to bring a private biotech asset to the public markets. For investors, DNAD should therefore be viewed primarily as a financial vehicle rather than as an operating company with recurring product revenue prior to a merger. Its competitive position was tied to its ability to identify an attractive life sciences target and complete a transaction on terms that would appeal to both public-market investors and the target company. In the crowded SPAC environment, especially in healthcare and biotech, differentiation typically depends on the sponsor’s network, the perceived quality of the target, and the post-deal equity story. Social Capital Suvretta Holdings Corp. IV’s model fit that playbook: there were no standalone commercial products or services under the blank-check entity itself; the core assets were the IPO proceeds, the listed platform, and the sponsor team. A key recent development was disclosed on May 26, 2023, when the company said it would not be able to complete its initial business combination by the deadline of July 2, 2023. That announcement is the most important event in the company’s public history because it signals that the original SPAC transaction did not close on schedule. As a result, any SEO-oriented investor description should emphasize the vehicle’s structure, sponsor pedigree, and intended biotech focus rather than imply a mature operating franchise. For French-speaking investors tracking U.S. equities, the references to NASDAQ and the United States are central to understanding the listing venue, disclosure regime, and SPAC-specific risk profile.